Galera Therapeutics Stock News

MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop

Galera Therapeutics is developing drugs that reduce side effects from anti-cancer radiotherapy and improve the treatment outcome.

Galera Therapeutics press release (GRTX): Q4 GAAP EPS of -$0.64 beats by $0.10.As of December 31, 2021, the company had cash, cash equivalents and short-term investments of…

Galera Therapeutics Inc (GRTX) shares closed this week 25.3% lower than it did at the end of last week. The stock is currently down 25.3% year-to-date, down 66.9% over the past 12 months, and down 71.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $4.65 and as low as $3.40 this week.Shares closed 73.6% below its 52-week high and 188.2% above its 52-week low.Trading volume this week was 21.0% lower than the 10-day average and 94.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 1488.7% The company's stock price performance over the past 12 months lags the peer average by 116.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop

Which penny stocks are you buying right now? The post Top Penny Stocks to Buy in 2022?

Galera Therapeutics Inc (GRTX) shares closed today 16.4% higher than it did at the end of yesterday. The stock is currently down 56.9% year-to-date, down 59.9% over the past 12 months, and down 63.3% over the past five years. Today, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 1.8%. Trading Activity Shares traded as high as $4.73 and as low as $2.52 this week.Shares closed 66.1% below its 52-week high and 270.6% above its 52-week low.Trading volume this week was 45.8% higher than the 10-day average and 303.7% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 90.8% The company's stock price performance over the past 12 months lags the peer average by 94.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Galera Therapeutics, Inc. (NASDAQ:GRTX) Director Linda West acquired 20,000 shares of the companys stock in a transaction dated Friday, December 17th. The shares were purchased at an average cost of $2.74 per share, for a total transaction of $54,800.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through []

NEW YORK , Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRLD, MNSO, GRTX, SPRB, and PRPL. Full story available on Benzinga.com

PALM BEACH, Fla. , Dec. 21, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the breast and red patches on the skin. Obesity, lack of physical activity, excessive radiation exposure, and alcohol use are all risk factors for breast cancer. Breast cancer is more prevalent in developed countries than it is in developing countries. Post diagnosis, cancer therapy requires different procedures depending upon the form and severity of cancer. The cancer care market is increasing at a substantial pace due to the rise in the occurrence of cancer cases, growing knowledge among people about different stages, and availability of treatment of cancer. Breast cancer treatment relies on different factors, such as breast cancer origin, tumor size, and breast cancer phase, and cancer grade. Operations, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and bone-led therapy are some of the most popular approaches used in the management of breast cancer.

Which penny stocks are you watching right now? The post Trending Penny Stocks to Buy Today?

The stock price of Galera Therapeutics Inc (NASDAQ: GRTX) increased by 28.04% today. This is why it happened.

Citi has raised the price target on Galera Therapeutics Inc (NASDAQ:GRTX) to $20 (suggesting 361% upside) from $11 and maintained a Buy rating.  Analyst Yigal Nochomovitz is re-introducing avaso

Which penny stocks are you watching as 2021 comes to an end? The post Check These Penny Stocks Out For Your Watchlist As the Market Dips appeared first on Penny Stocks to Buy, Picks, News and Informat

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news. Among the regulatory decisions for the week, the Food and Drug Administration gave the green light to argenx SE''s (NASDAQ: ARGX ) efgartigimod for the treatment of generalized myasthenia gravis. AstraZeneca plc (NASDAQ: AZN ) and Amgen, Inc. (NASDAQ: AMGN ) announced an FDA nod for their Tezspire as a treatment option for severe asthma for those aged 12 years and older. Bristol-Myers Squibb Company ''s (NYSE: BMY ) Orencia was approved for the prophylactic treatment of acute graft-versus-host disease. Calliditas Therapeutics AB (publ) (NASDAQ: CALT ) scored an FDA win for Tarpeyo, the first-approved treatment to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. Galera Therapeutics, Inc. (NASDAQ: Full story available on Benzinga.